Skip to main content

Advertisement

SpringerLink
Log in

Assessing disease activity and disease activity indices for inflammatory bowel disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

A crucial step in the development of clinical trials to determine the efficacy of various therapies for inflammatory bowel disease (IBD) has been the creation of activity indices. This article reviews the major components and operating characteristics of clinical activity indices commonly used in randomized, controlled trials of IBD therapy. In addition, the paper provides a brief overview of the developmental requirements for any new index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance

  1. Winship DH, Summers RW, Singleton JW, et al.: National Cooperative Crohn’s Disease Study: study design and conduct of the study. Gastroenterology 1979, 77:829–842.

    PubMed  CAS  Google Scholar 

  2. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976, 70:439–444. Classic reference initiating the CDAI.

    PubMed  CAS  Google Scholar 

  3. Sandborn WJ, Feagan BG, Hanauer SB, et al.: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002, 122:512–530. The current definitive review of activity indices in IBD.

    Article  PubMed  Google Scholar 

  4. de Dombal FT, Softley A: IOIBD Report no 1: Observer variation in calculating indices of severity and activity in Crohn’s disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987, 28:474–481.

    Google Scholar 

  5. Harvey RF, Bradshaw JM: A simple index of Crohn’s-disease activity. Lancet 1980, 1:514.

    Article  PubMed  CAS  Google Scholar 

  6. Myren J, Bouchier IA, Watkinson G, et al.: The OMGE multinational inflammatory bowel disease survey 1976–1986: a further report on 3175 cases. Scand J Gastroenterol 1988, 144 (Suppl):111–119.

    Google Scholar 

  7. Wright JP, Marks IN, Parfitt A: A simple clinical index of Crohn’s disease activity: the Cape Town index. S Afr Med J 1985, 68:502–503.

    PubMed  CAS  Google Scholar 

  8. van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH: An index of inflammatory activity in patients with Crohn’s disease. Gut 1980, 21:279–286.

    PubMed  Google Scholar 

  9. Irvine EJ: Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995, 20:27–32.

    Article  PubMed  CAS  Google Scholar 

  10. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  11. Sandler RS, Jordan MC, Kupper LL: Development of a Crohn’s index for survey research. J Clin Epidemiol 1988, 41:451–458.

    Article  PubMed  CAS  Google Scholar 

  12. Hyams JS, Ferry GD, Mandel FS, et al.: Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991, 12:439–447.

    PubMed  CAS  Google Scholar 

  13. Truelove SC, Witts LJ: Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955, 2:1041–1048.

    PubMed  CAS  Google Scholar 

  14. Powell-Tuck J, Day DW, Buckell NA, et al.: Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982, 27:533–537.

    Article  PubMed  CAS  Google Scholar 

  15. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987, 317:1625–1629.

    Article  PubMed  CAS  Google Scholar 

  16. Sutherland LR, Martin F, Greer S, et al.: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894–1898.

    PubMed  CAS  Google Scholar 

  17. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82–86.

    PubMed  CAS  Google Scholar 

  18. Irvine EJ, Feagan B, Rochon J, et al.: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287–96. Important early reference incorporating quality of life into IBD assessment.

    PubMed  CAS  Google Scholar 

  19. Guyatt G, Mitchell A, Irvine EJ, et al.: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804–810.

    PubMed  CAS  Google Scholar 

  20. Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  21. Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836–841.

    Article  PubMed  CAS  Google Scholar 

  22. Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996, 110:45–51.

    Article  PubMed  CAS  Google Scholar 

  23. Drossman DA, Patrick DL, Mitchell CM, et al.: Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989, 34:1379–1386.

    Article  PubMed  CAS  Google Scholar 

  24. Drossman DA, Leserman J, Li ZM, et al.: The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991, 53:701–712.

    PubMed  CAS  Google Scholar 

  25. Hjortswang H, Strom M, Almeida RT, Almer S: Evaluation of the RFIPC, a disease-specific health-related quality of life questionnaire, in Swedish patients with ulcerative colitis. Scand J Gastroenterol 1997, 32:1235–1240. Another classic reference.

    Article  PubMed  CAS  Google Scholar 

  26. Reproducibility of colonoscopic findings in Crohn’s disease: a prospective multicenter study of interobserver variation. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987, 32:1370–1379.

  27. Modigliani R, Mary JY, Simon JF, et al.: Clinical, biological, and endoscopic picture of attacks of Crohn’s disease: evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811–818. Important prospective endoscopic study that validated the CDEIS.

    PubMed  CAS  Google Scholar 

  28. Mary JY, Modigliani R: Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983–989.

    PubMed  CAS  Google Scholar 

  29. D’Haens G, Van Deventer S, et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999, 116:1029–1034.

    Article  PubMed  CAS  Google Scholar 

  30. Landi B, Anh TN, Cortot A, et al.: Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992, 102:1647–1653.

    PubMed  CAS  Google Scholar 

  31. Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.

    PubMed  CAS  Google Scholar 

  32. Hellers G, Cortot A, Jewell D, et al.: Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. The IOIBD Budesonide Study Group. Gastroenterology 1999, 116:294–300.

    Article  PubMed  CAS  Google Scholar 

  33. Caprilli R, Andreoli A, Capurso L, et al.: Oral mesalazine (5-aminosalicylic acid, Asacol) for the prevention of postoperative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994, 8:35–43.

    Article  PubMed  CAS  Google Scholar 

  34. Florent C, Cortot A, Quandale P, et al.: Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 1996, 8:229–233.

    Article  PubMed  CAS  Google Scholar 

  35. Rutgeerts P, Hiele M, Geboes K, et al.: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995, 108:1617–1621.

    Article  PubMed  CAS  Google Scholar 

  36. Baron JH, Connell AM, Lennard-Jones JE: Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964, 1:89–92.

    Article  PubMed  CAS  Google Scholar 

  37. D’Haens GR, Geboes K, Peeters M, et al.: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262–267.

    Article  PubMed  CAS  Google Scholar 

  38. Truelove SC, Richards WCD: Biopsy studies in ulcerative colitis. BMJ 1956, 1:1315–1318.

    PubMed  CAS  Google Scholar 

  39. Lofberg R, Ostergaard Thomsen O, et al.: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994, 8:623–629.

    Article  PubMed  CAS  Google Scholar 

  40. Mulder CJ, Endert E, van der Heide H, et al.: Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis: an adrenocortical approach. Neth J Med 1989, 35:18–24.

    PubMed  CAS  Google Scholar 

  41. Sandborn WJ, Tremaine WJ, Schroeder KW, et al.: A placebocontrolled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994, 106:1429–1435.

    PubMed  CAS  Google Scholar 

  42. Wright JP, Young GO, Tigler-Wybrandi N: Predictors of acute relapse of Crohn’s disease: a laboratory and clinical study. Dig Dis Sci 1987, 32:164–170.

    Article  PubMed  CAS  Google Scholar 

  43. Irvine EJ, Feagan BG, Wong CJ: Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996, 49:1177–1185.

    Article  PubMed  CAS  Google Scholar 

  44. Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987, 40:171–178.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Community Health Sciences and Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1, Calgary, AB, Canada

    Feng Xiao Li MD, PhD & Lloyd R. Sutherland MDCD, MSc, FRCPC, FACP

Authors
  1. Feng Xiao Li MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lloyd R. Sutherland MDCD, MSc, FRCPC, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, F.X., Sutherland, L.R. Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 4, 490–496 (2002). https://doi.org/10.1007/s11894-002-0025-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-002-0025-z

Keywords

Search

Navigation